Uppsala, Sweden – 9 March 2023 – Biotage AB (publ) (“Biotage”) today announced that Lars Bäckman will retire from his position as Chief Legal Officer, after more than 16 years with the company. Lars is part of Group Management as Senior Executive, and he will leave Biotage effectively in September 2023.
Tomas Blomquist, CEO and President at Biotage, said: “I want to thank Lars for his many years of service at Biotage. Lars has had a central role driving the Biotage growth journey, not the least by managing the mergers and acquisitions (M&A) activities over the years, but also as a highly appreciated member of the senior management team. Most recently, he managed and coordinated the acquisition of Astrea Bioseparations, a high-growth chromatography solutions provider. The acquisition will extend Biotage’s chromatography franchise into the higher-growth and larger bioprocessing segment, while also increasing exposure to biologics and advanced therapeutics customers.”
Lars Bäckman, Chief Legal Officer at Biotage, said: “I am honored to have been part of the Biotage growth journey and I am looking forward to following Biotage in the future. I take the opportunity to thank all my colleagues around the world for making my Biotage career such a joyful ride.”
For more information, reach out to:
President and CEO
+46 705 23 01 63
+46 761 42 26 12
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.